Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Non-randomised, Open-label, Single Agent Phase II Study to Determine the Clinical Benefit of Trastuzumab Emtansine (T-DM1) in HER2-positive Metastatic Breast Cancer Patients With Brain Metastasis

Trial Profile

Multicenter, Non-randomised, Open-label, Single Agent Phase II Study to Determine the Clinical Benefit of Trastuzumab Emtansine (T-DM1) in HER2-positive Metastatic Breast Cancer Patients With Brain Metastasis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2018

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Acronyms KIARA
  • Most Recent Events

    • 28 Nov 2018 Planned End Date changed from 1 Jul 2020 to 27 Aug 2018.
    • 28 Nov 2018 Planned primary completion date changed from 1 Jul 2020 to 27 Aug 2018.
    • 28 Nov 2018 Planned initiation date changed from 1 Jul 2017 to 23 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top